203Pb与212Pb放射诊疗的剂量学与显像进展
本文综述以212Pb靶向α治疗为核心的放射诊疗对,其同位素伙伴203Pb作为γ发射替代物用于定量SPECT显像。文章总结SPECT显像设备进步、连续203Pb SPECT/CT采集与药代动力学建模结合的临床剂量学流程,以及器官级与体素级剂量学和微剂量建模如何支持个体化治疗计划与预测性活度定量。
要点
- 203Pb作为212Pb的γ发射替代物,可用于定量SPECT显像与患者个体化剂量学。
- SPECT设备从NaI(Tl)双探头到CZT多探测器提升了空间分辨率与定量准确性。
- 连续203Pb SPECT/CT采集结合药代动力学建模可生成时间-活度曲线与吸收剂量估计。
核心结论
- 203Pb/212Pb诊疗对具有转化潜力,其显像与剂量学进展共同支持定量、个体化、诊疗一体化的核素治疗。
研究设计与样本
- 本文为综述,评估212Pb靶向α治疗的临床应用、203Pb替代显像、γ相机性能、剂量学流程与预测性活度定量。
主要发现
- 212Pb的α粒子具有高线性能量传递和短路径长度,可精确杀伤肿瘤细胞并保护周围健康组织。
- 203Pb作为γ发射替代物为患者个体化剂量学与治疗计划提供必要信息。
- SPECT显像进步提升了空间分辨率、定量准确性与病灶可探测性,支持快速扫描与活度定量改善。
临床怎么用
- 临床可整合连续203Pb SPECT/CT采集、药代动力学建模与基于图像的活度定量,生成时间-活度曲线与吸收剂量估计。
- 器官级与体素级剂量学结合先进重建与微剂量建模可细化剂量计算,支持个体化治疗计划。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeted alpha therapy (TAT) with 212Pb is rapidly emerging as a potent modality for cancer treatment due to the high linear energy transfer and short path length of α-particles, which enable precise tumor cell killing while sparing surrounding healthy tissue. Its elementally identical theranostic partner, 203Pb, functions as a γ-emitting surrogate for quantitative SPECT imaging, providing essential information for patient-specific dosimetry and treatment planning. Advances in SPECT imaging, ranging from NaI(Tl)-based dual-head systems to CZT multi-detector gamma cameras, have enhanced spatial resolution, quantitative accuracy, and lesion detectability, enabling rapid patient scanning and improved activity quantification for dosimetry. Clinical dosimetry workflows that integrate serial 203Pb SPECT/CT acquisitions, pharmacokinetic modeling, and image-based activity quantification facilitate reliable generation of time-activity curves and absorbed dose estimates. Organ-level and voxel-based dosimetry, combined with advanced reconstruction and microdosimetric modeling, further refine dose calculations, supporting individualized therapy planning. Collectively, these developments highlight the translational potential of the 203Pb/212Pb theranostic pair. The aim of this review is to provide a comprehensive assessment of 212Pb-TAT, encompassing clinical applications, surrogate imaging with 203Pb, gamma camera performance, dosimetry workflows, and predictive activity quantification, illustrating how these advances collectively enable quantitative, patient-specific, and theranostic-integrated radionuclide therapy.
引用
- Ramonaheng K, Qebetu M, Banda K, et al. Advances in Dosimetry and Imaging for 203Pb and 212Pb Radiotheranostics. Semin Nucl Med. 2025. PMID: 41062349. doi:10.1053/j.semnuclmed.2025.09.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。